Literature DB >> 33727353

Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication.

Lily E Adams1, Kenneth H Dinnon1, Yixuan J Hou2, Timothy P Sheahan2, Mark T Heise3,4,5, Ralph S Baric3,2,5.   

Abstract

The angiotensin-converting enzyme 2 (ACE2) receptor is a major severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host range determinant, and understanding SARS-CoV-2-ACE2 interactions will provide important insights into COVID-19 pathogenesis and animal model development. SARS-CoV-2 cannot infect mice due to incompatibility between its receptor binding domain and the murine ACE2 receptor. Through molecular modeling and empirical in vitro validation, we identified 5 key amino acid differences between murine and human ACE2 that mediate SARS-CoV-2 infection, generating a chimeric humanized murine ACE2. Additionally, we examined the ability of the humanized murine ACE2 receptor to permit infection by an additional preemergent group 2B coronavirus, WIV-1, providing evidence for the potential pan-virus capabilities of this chimeric receptor. Finally, we predicted the ability of these determinants to inform host range identification of preemergent coronaviruses by evaluating hot spot contacts between SARS-CoV-2 and additional potential host receptors. Our results identify residue determinants that mediate coronavirus receptor usage and host range for application in SARS-CoV-2 and emerging coronavirus animal model development.IMPORTANCE SARS-CoV-2 (the causative agent of COVID-19) is a major public health threat and one of two related coronaviruses that have caused epidemics in modern history. A method of screening potential infectible hosts for preemergent and future emergent coronaviruses would aid in mounting rapid response and intervention strategies during future emergence events. Here, we evaluated determinants of SARS-CoV-2 receptor interactions, identifying key changes that enable or prevent infection. The analysis detailed in this study will aid in the development of model systems to screen emergent coronaviruses as well as treatments to counteract infections.
Copyright © 2021 Adams et al.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; host range; receptors; virus-host interactions

Mesh:

Substances:

Year:  2021        PMID: 33727353     DOI: 10.1128/mBio.03149-20

Source DB:  PubMed          Journal:  mBio            Impact factor:   7.867


  2 in total

1.  ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology.

Authors:  Riem Gawish; Philipp Starkl; Lisabeth Pimenov; Anastasiya Hladik; Karin Lakovits; Felicitas Oberndorfer; Shane Jf Cronin; Anna Ohradanova-Repic; Gerald Wirnsberger; Benedikt Agerer; Lukas Endler; Tümay Capraz; Jan W Perthold; Domagoj Cikes; Rubina Koglgruber; Astrid Hagelkruys; Nuria Montserrat; Ali Mirazimi; Louis Boon; Hannes Stockinger; Andreas Bergthaler; Chris Oostenbrink; Josef M Penninger; Sylvia Knapp
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.140

2.  Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.

Authors:  Tasnim Saifudin Zakir; Tao Meng; Lee Ching Pei Carmen; Justin Jang Hann Chu; Raymond Tzer Pin Lin; Mookkan Prabakaran
Journal:  Viruses       Date:  2022-01-24       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.